OKYO Pharma Initiated Phase 3 Urcosimod Trial
The company enrolled its first patients in a study targeting neuropathic corneal pain.
Updated on Oct. 6, 2026 in Biotech
Live Poll
Should medical researchers fast-track clinical trials for treatments targeting debilitating chronic pain conditions?
OKYO Pharma has begun its Phase 3 clinical trial for urcosimod, a drug designed to treat neuropathic corneal pain. The study, known as the NEPTUNE trial, marks a significant step toward addressing a condition that currently lacks FDA-approved treatments.
Why it matters
Patients suffering from neuropathic corneal pain have no existing FDA-approved therapies, leaving a critical gap in medical care. This trial aims to provide a standardized, clinically tested intervention for individuals experiencing chronic ocular discomfort.
The study involves a clinical trial sample size testing a lipid-conjugated chemerin peptide agonist. Participants receive 4 drops of urcosimod daily over a treatment duration of 12 weeks.
The players
OKYO Pharma
This is a biopharmaceutical company focused on developing innovative therapies for inflammatory dry eye and ocular pain.
Toyos Clinic
This is a specialized medical facility located in Nashville, Tennessee, serving as the first site for the NEPTUNE trial.
The details
The NEPTUNE trial evaluates the efficacy of urcosimod using the VAS score to measure changes in ocular pain. Research is being conducted across multiple clinical sites in the United States, as well as in Italy, Spain, and France.
Timeline
October 6, 2026: First patients were enrolled in the clinical trial.
The Big Picture
This development represents a significant paradigm shift in ophthalmology, as it targets a specific pain condition rather than general surface dryness. It follows the structural transparency protocols established by the clinicaltrials.gov registry to validate medical breakthroughs.
For patients suffering from chronic ocular pain, this trial signals the potential for future access to a dedicated therapeutic option. Currently, individuals are limited by the lack of approved treatments, making the successful outcome of this study vital for future care.
The takeaway
The initiation of the NEPTUNE trial highlights the push to find relief for chronic, untreatable eye pain. Patients should continue to monitor updates from their eye care providers regarding clinical trial availability.
What happens next
The company expects to activate additional clinical sites at leading U.S. medical centers as the trial progresses.
Further reading
For more information on current drug research, visit the Biotech section.
More information
Review the full details of the clinicaltrials.gov NEPTUNE study information.
Live Poll
Should medical researchers fast-track clinical trials for treatments targeting debilitating chronic pain conditions?
